Abstract
The aim of this study was to develop a suppository dosage form based on the bacteriophages cocktail. To achieve this, using patented technology, highly active sterile phage lysates were obtained, auxiliary components were selected and the finished dosage form was designed - suppositories with the initial high specific antibacterial activity that persists after absorption through the intestinal mucosa, which was confirmed during pharmacokinetic studies in experimental animals.During the development of suppositories based on bacteriophages cocktail microbiological, molecular genetics, biotechnological methods and preclinical studies were used.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
